Search research articles
Contact Us
Filters
Showing results (51-60 of 92) with videos related to
Page
of 10
Sort By:
Leukemia & Lymphoma
|
May 10, 2018
Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytes
Sreenivasulu Gunti, Sarah E M Herman, Raju V S R K Gottumukkala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2020
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib
Anfal Alsadhan, Jean Cheung, Michael Gulrajani, et al.
Cancer Research
|
December 1, 2018
TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib
Eman L Dadashian, Erin M McAuley, Delong Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2020
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
Inhye E Ahn, Xin Tian, David Ipe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2017
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model
Carsten U Niemann, Helena I Mora-Jensen, Eman L Dadashian, et al.
Blood
|
March 8, 2011
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia
Sarah E M Herman, Rosa Lapalombella, Amber L Gordon, et al.
Blood
|
March 22, 2014
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
Holbrook E Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, et al.
Blood
|
March 23, 2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E M Herman, Amber L Gordon, Erin Hertlein, et al.
Leukemia & Lymphoma
|
November 16, 2021
CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage
Arshia Soleimani, Alba Navarro, Delong Liu, et al.
The AAPS Journal
|
September 8, 2012
Pharmacokinetics and tissue disposition of lenalidomide in mice
Darlene M Rozewski, Sarah E M Herman, William H Towns, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 92) with videos related to
Sort By:
Page
of 10
Leukemia & Lymphoma
|
May 10, 2018
Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytes
Sreenivasulu Gunti, Sarah E M Herman, Raju V S R K Gottumukkala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2020
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib
Anfal Alsadhan, Jean Cheung, Michael Gulrajani, et al.
Cancer Research
|
December 1, 2018
TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib
Eman L Dadashian, Erin M McAuley, Delong Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2020
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
Inhye E Ahn, Xin Tian, David Ipe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2017
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model
Carsten U Niemann, Helena I Mora-Jensen, Eman L Dadashian, et al.
Blood
|
March 8, 2011
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia
Sarah E M Herman, Rosa Lapalombella, Amber L Gordon, et al.
Blood
|
March 22, 2014
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
Holbrook E Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, et al.
Blood
|
March 23, 2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E M Herman, Amber L Gordon, Erin Hertlein, et al.
Leukemia & Lymphoma
|
November 16, 2021
CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage
Arshia Soleimani, Alba Navarro, Delong Liu, et al.
The AAPS Journal
|
September 8, 2012
Pharmacokinetics and tissue disposition of lenalidomide in mice
Darlene M Rozewski, Sarah E M Herman, William H Towns, et al.
Page
of 10